MARK G FOLETTA

CIK 1236389 · EVP & Chief Financial Officer · last filed 2026-06-01

MARK G FOLETTA is an EVP & Chief Financial Officer who has filed 117 SEC Form 4 insider transactions across 10 companies since 2007. The most recent filing, for DXCM, was dated Jun 1, 2026. Across all open-market trades the lifetime net is −$7.7M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $5.4M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$5.43M

Companies

10

Total Filings

117

Lifetime Open-Market Net

-$7.75M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
DXCM Director 63,183 $75.37 $4.76M -$5.33M 37 2026-06-01
AMN Director 21,598 $30.80 $665.2K -$1.09M 20 2026-05-04
ENTA Director $11.90 $0 7 2026-03-13
Forte Biosciences, Inc. (TOCA) Delisted EVP & Chief Financial Officer 15,042 $71.5K 7 2019-10-04
Regulus Therapeutics Inc. (RGLS) Delisted Director 81,910 $8.16 $668.4K $76.4K 7 2017-12-06
AMN HEALTHCARE SERVICES INC (AHS) Delisted Director 5,532 $0 4 2016-04-22
BIOCEPT INC (BIOC) Delisted Interim CFO $0.43 $0 1 2015-09-02
AMBIT BIOSCIENCES CORP (AMBI) Delisted Director $0.54 $0 2 2014-11-12
AMYLIN PHARMACEUTICALS INC (AMLN) Delisted SVP, Chief Financial Officer 81,344 -$1.48M 25 2012-07-26
ANADYS PHARMACEUTICALS INC (ANDS) Delisted Director $0 6 2011-05-27

Recent Filings

117 filings
Form 4 transactions across all companies, newest first.
Filed Symbol Action Net Shares Net $ Link
2026-06-01 DXCM Grant (A) +6,331 $0 EDGAR
2026-05-11 DXCM Gift (G) $0 EDGAR
2026-05-04 AMN Mixed +8,325 $0 EDGAR
2026-03-13 ENTA Grant (A) $0 EDGAR
2025-08-18 DXCM Sell (S) −2,750 -$222.9K EDGAR
2025-07-17 DXCM Sell (S) −2,750 -$234.2K EDGAR
2025-06-18 DXCM Sell (S) −2,750 -$228.6K EDGAR
2025-05-12 DXCM Mixed +5,731 $0 EDGAR
2025-05-06 AMN Grant (A) $0 EDGAR
2025-04-21 AMN Exer (M) +3,019 $0 EDGAR
Showing 110 of 117
Page 1 of 12
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.